Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals
Steven D LaRowe, Pascale Mardikian, Robert Malcolm, Hugh Myrick, Peter Kalivas, Krista McFarland, Michael Saladin, Aimee McRae, Kathleen Brady, Steven D LaRowe, Pascale Mardikian, Robert Malcolm, Hugh Myrick, Peter Kalivas, Krista McFarland, Michael Saladin, Aimee McRae, Kathleen Brady
Abstract
A double-blind placebo-controlled crossover Phase I trial was conducted to assess the safety and tolerability of N-Acetylcysteine (NAC) in healthy, cocaine-dependent humans. Thirteen participants attended a three-day hospitalization in which they received placebo or NAC. Subjects were crossed over to receive the opposite medication condition during a second three-day hospitalization, which occurred the following week. Across placebo and NAC conditions, only mild side effects were noted, and the number of subjects reporting side effects did not differ. There were trends for a greater reduction in withdrawal symptoms and craving within the NAC condition. These preliminary results suggest that NAC is well tolerated in healthy, cocaine-dependent individuals and may reduce cocaine-related withdrawal symptoms and craving.
Figures
Source: PubMed